Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 851-854

  Cervetti, G ^a   Galimberti, S ^a   Sordi, E ^a   Buda, G ^a   Orciuolo, E ^a   Cecconi, N ^a   Petrini, M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cladribine; Rituximab; Splenic marginal zone lymphoma

Indexed keywords

ACICLOVIR; CLADRIBINE; COTRIMOXAZOLE; DIPHENHYDRAMINE; FLUCONAZOLE; PARACETAMOL; RITUXIMAB;

ADULT; AGED; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER REGRESSION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; FEMALE; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPLENIC MARGINAL ZONE LYMPHOMA; STOMACH CARCINOMA; THROMBOCYTOPENIA;

2-CHLOROADENOSINE; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYADENOSINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77950302031     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp395     Document Type: Article

References (27)

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC 2001.
3. Troussard X, Valensi F, Duchayne E et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 1996; 93: 731-736.
4. Nathwani B, Anderson J, Armitage J et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non- Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999; 17: 2486-2492.
5. Berger F, Felman P, Thieblemont C et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950-1956.
6. Thieblemont C, Felman P, Callet-Bauchu E et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003; 4: 95-103.
7. Franco V, Florena AM, Stella M et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone lymphoma with or without villous lymphocytes. Cancer 2001; 91: 294-301.
8. Andouin J, Le Tourneau A, Molina T et al. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol 2003; 122: 404-412.
9. Chacon J, Mollejo M, Munoz E et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100: 1648-1654.
10. Arcaini L, Lazzarino M, Colombo N et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107: 4643-4649.
11. Lefrere F, Hermine O, Belanger C et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14: 573-575.
12. Iannitto E, Minardi V, Calvaruso G et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005; 75: 130-135.
13. Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CDA). Br J Haematol 1998; 100: 609.
14. Lefrere F, Hermine O, Francois S et al. Lack of efficacy of 2-chlorodeoxyadenosine in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000; 40: 113-117.
15. Riccioni R, Caracciolo F, Galimberti S et al. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003; 21: 163-168.
16. Hermine O, Lefrere F, Bronowicki JP et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
17. Keladi C, Rollor F, Park S et al. Response to antiviral treatment in hepatitis C virus associated marginal zone lymphomas. Leukemia 2004; 18: 1711-1716.
18. Arcaini L, Orlandi E, Scotti M et al. Combination of rituximab, cyclophosphamide and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004; 4: 250-252.
19. Bennett M, Sharma K, Yegena S et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005; 90: 856-858.
20. Tsimberidou AM, Catovsky D, Schlette E et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107: 125-135.
21. Fabbri A, Gozetti A, Lazzi S et al. Activity of rituximab in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma 2006; 6: 496-499.
22. Galimberti S, Brizzi S, Mameli F et al. An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection. Leuk Res 1999; 23: 921-929.
23. Lauria F, Bocchia M, Marotta G et al. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84(1): 22-25.
24. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 99: 158-161.
25. Cervetti G, Mechelli S, Riccioni R et al. High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol 2005; 23(6): 877-880.
26. Cervetti G, Galimberti S, Andreazzoli F et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol 2008; 143: 296-298.
27. Pelosini M, Focosi D, Fazzi R et al. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative haematological patients and review of literature. Ann Hematol 2008; 87: 405-412.